UNSPSC 51314342: Chlorpheniramine/phenylpropanolamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314342 Chlorpheniramine/phenylpropanolamine/pseudoephedrine is a Commodity code with sparse alignment between its nominal scope and recent state and local procurement activity. The three most recent opportunities tagged to this code show minimal connection to the specific cold-remedy pharmaceutical combination named: Seminole County, Florida is procuring naloxone and drug deactivation systems for community health support; the Texas Health and Human Services Commission has issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting generic multi-source pharmaceuticals and over-the-counter products broadly across state and local jurisdictions. The actual work being bought under this code does not appear to focus on the chlorpheniramine/phenylpropanolamine/pseudoephedrine combination in particular but rather spans emergency-response pharmaceuticals, prescription program infrastructure, and generic OTC product sourcing at scale across participating state agencies and health departments.

Recent activity shows issuing bodies spanning county health departments, state health commissions, and multi-state cooperative purchasing alliances. Geographically, the code sees activity in Florida, Texas, and Minnesota-led cooperative purchasing extending to Oregon and other participating jurisdictions. The Seminole County opportunity (IFB 60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding; the Texas HHS Commission RFI (HHS0017013, April 3, 2026) gathered vendor intelligence on direct-to-manufacturer prescription delivery capabilities; and the MMCAP RFP (S1070000015802, due March 26, 2026) solicited generic pharmaceuticals and OTC products across multiple wholesaler channels, with awards effective July 1, 2026, and a two-year initial term. The code shows limited recent transaction volume and weak alignment between its nominal pharmaceutical composition and the actual procurement patterns being tagged to it, signaling either taxonomy misclassification in submitted opportunities or minimal current demand specifically for chlorpheniramine/phenylpropanolamine/pseudoephedrine formulations.